Fig 1: Effects of fixed dose IL-7 treatment(A) Schematic representation of the IL-7 fixed-dose protocol. Four macaques received subcutaneous injection of three doses of 100 mg/kg (MC73, MC74; gray symbols) or 200 mg/kg (MF07, MF30; black symbols) of IL-7 administered every three days.(B) Plasma IL-7 levels collected at the indicated time points after each injection.(C) IL-7 trough levels in plasma were measured 24 h and 48 h after each injection.(D) Comparison of plasma IL-7 levels at 24 h and 48 h after last cytokine injections in the fixed-dose and step-dose regimen.(E) CXCL13 levels in plasma before (pre) and after last (post) fixed-dose treatment.(F) Frequency of B (CD20+) and T (CD3+) lymphocytes in LNMC at pre and post (2 days after last injection) (left panel). B to T cell ratio in LNMC at pre and post (right panel).(G) Frequency of B (CD20+) and T (CD3+) lymphocytes in PBMC at pre and post (2 days after last injection) (left panel). B to T cell ratio in PBMC at pre and post (right panel).(H) Changes of frequency of GC-Tfh within CD4+T cells (left panel) and frequency of proliferating (Ki67+) GC-Tfh (CXCR5hi PD-1hi) (right panel).(I) Frequency of pDC in total LNMC (left panel) and fold change (right panel).